OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has signed an agreement with the Instituto de Química Orgánica General (“IQOG”) of the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC) based in Madrid. The IQOG is an international renowned centre in the synthesis, analysis, and the study of the biological behaviour of organic compounds in humans.
This agreement will enable OptiBiotix to progress its pipeline of novel oligosaccharides (carbohydrates that consists of a small number of sugars) identified by its OptBiotic® technology platform to testing in human studies.
The agreement with IQOG contracts them to:-
•Scale up the pipeline of novel oligosaccharides identified by the OptiBiotic® technology platform
•Purify the novel oligosaccharides to the desired level (>85%) for laboratory testing
•Analyse the oligosaccharides for their organoleptic (taste, texture, aftertaste) properties
•Assess the oligosaccharides for their microbiome modulating properties
This work is the final stage of the laboratory programme to identify calorie-free oligosaccharides with the potential to selectively enhance the growth rate of specific microbial strains and species to modulate the human microbiome to prevent, manage, and treat disease. Oligosaccharides showing commercial potential will commence human studies in 2016.
Stephen O’Hara, CEO of OptiBiotix, commented: “The last few months have seen substantial progress in reducing the technical risks associated with this exciting programme designed to create low calorie, sweet oligosaccharides, which could be used to reduce chronic lifestyle disease such as heart disease, obesity and diabetes. If successful, this work creates the opportunity to replace ‘unhealthy’ sugars in many food products with oligosaccharides which can improve health, and herald a new paradigm in the food industry. We are particularly pleased that international commercial partners have recognised the opportunity presented by this work and are including their own strains in the final stages of this development programme.”
See the article in full at Optibiotix-ir.com